Dudediligence.

Arcutis Biotherapeutics, Inc

ARQTNASDAQ · Pharmaceutical Preparations
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$44.8MSep ’24$69.4MDec ’24$63.8MMar ’25$81.5MJun ’25$99.2MSep ’25$127.5MDec ’25$105.4MMar ’26$129.9MJun ’26
Net income, by quarter
−$41.5MSep ’24−$10.8MDec ’24−$25.1MMar ’25−$15.9MJun ’25$7.4MSep ’25$17.4MDec ’25−$11.3MMar ’26$15.0MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue$0.00$3.7M$59.6M$166.5M$372.1M
Gross profit$0.00$2.9M$54.6M$147.4M$335.4M
Operating income−$206.5M−$301.6M−$241.1M−$128.4M−$12.2M
Net income−$206.4M−$311.5M−$262.1M−$140.0M−$16.1M
Operating cash flow−$174.6M−$257.7M−$247.1M−$112.2M−$5.6M
Free cash flow−$175.6M−$258.0M−$247.5M−$112.3M−$6.3M
Cash$98.0M$54.9M$89.3M$72.0M$42.9M
Debt$72.3M$197.8M$201.8M$107.2M$109.0M
Shares outstanding50.3M61.0M96.8M117.8M123.3M